Cover Story
- SUPRDOG Opens Waitlist for AI-Powered Biological Intelligence Platform for Dogs
Featured Article
- Pet Insurance Explained
Product Launch
- Dechra Launches Domidine in the US
- Standard Process Launches GI Soothing Supplement for Dogs and Cats
- Cronus Adds Robenacoxib for Pet Pain Care
Facility Expansion
- Elanco Expands Kansas Facility to Scale mAb Manufacturing
SUPRDOG Opens Waitlist for AI-Powered Biological Intelligence Platform for Dogs
Product Launch
SUPRDOG has opened the waitlist for an AI-enabled biological intelligence platform designed to help dog parents better understand their pets’ health by connecting biological signals with everyday factors such as nutrition, hydration, exercise, supplementation, and environmental exposure.
Key Highlights
- Core intelligence layer: FetchIQ, which interprets biological and lifestyle data to establish an individual dog’s baseline and detect meaningful changes.
- Operates on a “Learn. Act. Prove. Repeat.” model to establish baselines, guide interventions, track outcomes, and refine insights over time.
- Positioned as a biological intelligence layer (not a food, supplement, marketplace, or diagnostic) that integrates multiple health and lifestyle signals.
- Designed to complement veterinary care by helping owners identify changes earlier and have more informed discussions with veterinarians.
Impact
SUPRDOG’s approach reflects a broader move toward personalized, data-driven pet wellness, helping owners evaluate whether changes in diet, supplements, exercise, or routines are actually benefiting their individual dog. If adopted, the platform could become an additional decision-support layer within the evolving canine health ecosystem.
Pet Insurance Explained
A sudden illness, accident, or emergency procedure can turn an ordinary veterinary visit into a significant expense. Pet insurance can help reduce some of that financial pressure, but policies vary considerably in what they cover, what they exclude, and how reimbursement works.
At its simplest, pet insurance is designed to help cover eligible veterinary expenses. Depending on the policy, this may include accidents, illnesses, diagnostic tests, surgery, hospitalization, medications, and treatment for chronic or hereditary conditions. Some plans may also offer optional coverage for routine or preventive care.
However, the details matter. Before choosing a policy, pet owners should check pre-existing condition exclusions, waiting periods, deductibles, reimbursement levels, and annual or lifetime limits. These factors can significantly affect how much of a veterinary bill the owner ultimately pays.
Another important consideration is whether the policy suits the individual pet. Age, breed, existing health history, and likely healthcare needs can influence which types of coverage are most useful. A cheaper policy isn’t necessarily the most suitable if it excludes conditions your pet may be more likely to develop.
It’s also worth understanding how claims are handled. Policies can differ in how expenses are reimbursed, how quickly claims are processed, and whether owners have access to online claim tracking or other support services.
Ultimately, pet insurance isn’t about predicting whether your pet will become sick. It’s about being financially prepared if they do. Reading the policy carefully, comparing coverage rather than just premiums, and understanding exclusions before enrolling can help owners make a decision that works for both their pet’s healthcare needs and their budget.
Product Launch
Dechra has launched Domidine (detomidine hydrochloride) in the US, adding an established equine sedative & analgesic used to facilitate minor surgical and diagnostic procedures in horses.
Key Highlights
- Domidine has been used internationally for more than a decade, with 7+ million doses administered globally since 2016 across Europe, the UK, Canada, and Mexico.
- Indicated to provide sedation and analgesia for diagnostic imaging, minor surgical interventions, clinical education, and other routine equine procedures.
- Positioned as a cost-effective detomidine option for U.S. equine practices, compatible with existing sedation protocols.
Impact
The launch broadens the range of detomidine-based sedation choices available to US equine veterinarians, potentially improving access and cost flexibility for routine procedures. It also strengthens Dechra’s equine specialty portfolio with a product backed by extensive real-world clinical experience.
Product Launch
Standard Process has announced GI Soothing, a new whole food-based nutritional supplement in its Veterinary line for dogs and cats. Available for preorder, the formula combines probiotic, postbiotic, and botanical ingredients to support digestive comfort, healthy bowel function, and gastrointestinal balance.
Key Highlights
- Biotic Blend: Saccharomyces boulardii probiotic plus postbiotic Lactobacillus fermentate; each serving contains >1 billion CFU of S. boulardii at manufacture.
- Mucilage Blend: marshmallow root, organic slippery elm bark, and okra to provide soothing polysaccharides that support the GI lining.
- Intended for occasional digestive discomfort (e.g., diarrhea, sensitive stomach, stress-associated upset) and situations increasing GI/immune demands; suitable for all ages, including puppies.
- Incorporates whole-food ingredients (beet, Swiss chard, oats) from Standard Process’ 850+ acre certified organic farm.
Impact
GI Soothing adds a microbiome-focused, integrative nutrition option for veterinary professionals managing occasional GI instability in dogs and cats. The launch underscores the growing role of combined probiotic/postbiotic and plant-based support in companion animal digestive care
Product Launch
Cronus Pharma has launched Robenacoxib Injection, the first FDA-approved bioequivalent to Onsior (robenacoxib) Injection in the US. The product provides veterinarians with a new, potentially more cost-effective NSAID option for managing postoperative pain and inflammation in dogs and cats.
Key Highlights
- Indicated for postoperative pain/inflammation: dogs ≥4 months after soft tissue surgery; cats ≥4 months after orthopedic surgery, ovariohysterectomy, and castration.
- Treatment limited to a maximum of three days; supplied as 20 mg/mL in a 20 mL multidose vial.
- FDA-approved under ANADA #200-804 as bioequivalent to ONSIOR Injection, expanding choice within an established NSAID class.
- Available through national and regional veterinary distributors across the U.S.
Impact
The launch increases access to an FDA-approved robenacoxib option for postoperative pain control, potentially improving cost flexibility for practices while maintaining established efficacy and safety standards. Use is restricted to licensed veterinarians and limited to three days, in animals ≥4 months of age.
Facility Expansion
Elanco Animal Health has completed a 25,000-square-foot expansion of its Elwood, Kansas manufacturing facility to strengthen monoclonal antibody (mAb) production and support its growing biologics pipeline. The expansion addresses rising demand for antibody-based therapies, including Befrena (tirnovetmab) for canine allergic/atopic dermatitis and Trutect for canine parvovirus.
Key Highlights
- Increases mAb production capacity by more than 4x via new upstream and downstream processing equipment.
- Adds a pilot plant for accelerated process development and clinical material supply, a new QC laboratory, and additional manufacturing/support spaces.
- Befrena demand has reached ~2x initial expectations; expanded capacity is expected to support unconstrained supply by early 2027.
- Represents $120 million invested to date, with an additional $30 million planned through 2028 (primarily warehousing), totaling $150 million.
Impact
The expansion secures manufacturing scale for Elanco’s current mAb products and creates infrastructure to advance next-generation biologics. It reinforces Elanco’s position in the rapidly growing veterinary monoclonal antibody segment and supports reliable supply as new antibody-based therapies progress through the pipeline.
Making Sense of Pet Insurance
This edition of AnimalHealthX Weekly explains what pet owners should consider when choosing pet insurance, from coverage and exclusions to deductibles and reimbursement. The newsletter also features SUPRDOG’s AI-powered biological intelligence platform for canine health, Dechra’s US launch of Domidine, Standard Process’ GI Soothing supplement, Cronus’ FDA-approved robenacoxib injection, and Elanco’s Kansas facility expansion to scale monoclonal antibody manufacturing.
The Pulse of Global Animal Health
Enjoyed this edition? Share it with colleagues, partners, and fellow leaders shaping the future of animal health.
The industry is evolving at remarkable speed—from breakthrough biotech partnerships and regulatory milestones to AI-driven diagnostics and next-generation veterinary innovations. Staying informed isn’t just valuable—it’s essential to staying ahead.
Forward this newsletter, repost it, and help foster a more connected, informed, and forward-thinking global animal health community.
